Novo stock drops 15% as obesity drug falls short in key trial

Novo stock drops 15% as obesity drug falls short in key trial - Invezz# Novo stock drops 15% as obesity drug falls short in key trial[Health & pharma]Author[Utkarsh Roshan]Feb 23, 2026, 10:45 AM- Investors remain focused on obesity drug performance.- The trial miss sent Novo shares sharply lower.- Novo's CagriSema delivered less weight loss than Lilly's tirzepatide.Shares of Novo Nordisk fell sharply after the company said its next-generation obesity drug CagriSema delivered weaker weight-loss results than ...